Rights and permissions
About this article
Cite this article
High cost of dalteparin not worth added benefits in cancer. Pharmacoecon. Outcomes News 476, 4 (2005). https://doi.org/10.2165/00151234-200504760-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200504760-00004